TY  -  
T1  - Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes : A meta-analysis of randomized controlled trials 
SN  -  /  
UR  - http://hdl.handle.net/10138/325808 
T3  -  
A1  - Wang, Haining; Liu, Ye; Tian, Qing; Yang, Jin; Lu, Ran; Zhan, Siyan; Haukka, Jari; Hong, Tianpei 
A2  -  
PB  -  
Y1  - 2018 
LA  - eng 
AB  - Aims: To perform a meta-analysis of randomized controlled trials (RCTs), including 6 recently published large-scale cardiovascular outcome trials (CVOTs), to evaluate the risk of pancreatic cancer with incretin-based therapies in patients with type 2 diabetes (T2DM). Materials and Methods: For the period January 1, 2007 to May 1, 2017, the PubMed, Embase, Cochrane Central Register and databases were searched for RCTs in people with T2DM that compared incretin drugs with placebo or other antidiab... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - dipeptidyl peptidase-4 inhibitors; GLP-1 analogue; incretins; meta-analysis; type 2 diabetes; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; PRANDIAL INSULIN LISPRO; ADD-ON THERAPY; DOUBLE-BLIND; INITIAL COMBINATION; NON-INFERIORITY; CARDIOVASCULAR OUTCOMES; RECEPTOR ACTIVATION; CLINICAL-TRIAL; OPEN-LABEL; 3121 General medicine, internal medicine and other clinical medicine; 3142 Public health care science, environmental and occupational health 
N1  -   
PP  -  
ER  -